Therefore, targeting TLR9 and modulating TLR9 signaling using Hs90 inhibitors or siRNA to Hsp90 have emerged as important strategies for the treatment of self-nucleic acid-related autoimmune diseases, including SLE. The gene discussed is TLR9; the disease is systemic lupus erythematosus.